Form 8-K

8-K — Kairos Pharma, LTD.

Accession: 0001493152-26-039695

Filed: 2026-08-21

Period: 2026-08-21

CIK: 0001962011

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Material Modifications to Rights of Security Holders

Item: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-3.1 (ex3-1.htm)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

--12-31

0001962011

2026-08-21

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): August 21,

2026

Kairos

Pharma, Ltd.

(Exact

name of registrant as specified in its charter)

Delaware

001-42275

46-2993314

(State

or other jurisdiction

incorporation)

(Commission

File Number)

(IRS

Employer

Identification

No.)

2355

Westwood Blvd #139

Los

Angeles, CA

90064

(Address

of principal executive offices) (Zip Code)

(310)

948-2356

(Registrant’s

telephone number, including area code)

(Former

name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock $0.001 per share

KAPA

NYSE

American LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Cautionary

Statement Regarding Forward-Looking Statements

This

Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as

amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but

are not limited to, statements regarding the anticipated effective date of the Reverse Stock Split, the expected commencement of trading

on a split-adjusted basis, and the acceptance of the certificate of amendment to the certificate of incorporation by the

Secretary of State of the State of Delaware. Forward-looking statements are typically identified by words such as “will,”

“expect,” “anticipate,” “believe,” “intend,” “plan,” “estimate,”

“may,” “should,” “could,” and similar expressions. These statements are based on the Company’s

current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially

from those expressed or implied by such statements. The Company undertakes no obligation to update or revise any forward-looking statements,

whether as a result of new information, future events, or otherwise, except as required by law.

Item

3.03

Material

Modification to Rights of Security Holders.

the extent required by Item 3.03 of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in Item

5.03 of this Current Report on Form 8-K is incorporated by reference herein.

Item

5.03

Amendment

to Articles of Incorporation or Bylaws; Change in Fiscal Year.

the 2026 annual meeting of stockholders of Kairos Pharma, Ltd. (the “Company”) held on June 29, 2026 (the “Annual

Meeting”), the Company’s stockholders approved an amendment to the Company’s certificate of incorporation to authorize

one or more reverse stock splits of the Company’s outstanding shares of common stock, par value, $0.001 per share (the “Common

Stock”), at a reverse split ratio between one-for-three (1:3) and one-for-two hundred and fifty (1:250), as determined by the Board

of Directors of the Company (the “Board”) from time to time.

August 18, 2026, pursuant to such authority granted by the Company’s stockholders at the Annual Meeting, the Board authorized Company

management to complete a reverse stock split of one-for-seven (1:7) (the “Reverse Stock Split”) of the issued and outstanding

shares of Common Stock. On August 21, 2026, the Company filed a certificate of amendment to amend the certificate of incorporation

of the Company (the “Certificate of Amendment”) with the

Secretary of State of the State of Delaware, with an effective date of September 1, 2026 (the “Effective Date”).

The

Reverse Stock Split will become effective at the start of trading on September 1, 2026 (the “Effective Time”),

at which time it will begin trading on the NYSE American LLC (“NYSE American”) on a Reverse Stock Split-adjusted basis.

At such time,

every seven (7) shares of the Company’s issued and outstanding

Common Stock immediately prior to the Effective Time will automatically

be reclassified into one (1) share of Common Stock, without any change in the par value per share. The Reverse Stock Split will

also reduce the number of shares of Common Stock

issuable upon the exercise or vesting of the Company’s outstanding warrants and restricted stock units in proportion to the ratio

of the Reverse Stock Split and causes a proportionate increase in the exercise prices of such warrants.

The Reverse Stock Split will

not change the total number of authorized shares of Common

Stock or preferred stock.

The

new CUSIP number for the Company’s Common Stock following the Reverse Stock Split is 48301N203.

fractional shares will be issued as a result of the Reverse Stock Split. Stockholders who otherwise would be entitled to receive a fractional

share in connection with the Reverse Stock Split will receive one full share of the post-Reverse Stock Split Common Stock in lieu of

such fractional share. VStock Transfer LLC is acting as exchange agent for the Reverse Stock Split and will notify stockholders of record

regarding the Reverse Stock Split. Stockholders who hold their shares in book-entry form or in

“street name” (through a broker, bank or other holder of record) are not required to take any action.

The

foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to

the full text of the Certificate of Amendment, which is filed as Exhibit 3.1 to this report and incorporated by reference herein.

Item

7.01.

Regulation

FD Disclosure.

August 21, 2026, the Company issued a press release announcing the Reverse Stock Split. A copy of the press release is attached hereto

as Exhibit 99.1 and is incorporated herein by reference.

The

information in this Item 7.01 of this Current Report on Form 8-K, including the information contained in Exhibit 99.1 is being furnished

to the U.S. Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the

Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section,

and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange

Act, except as shall be expressly set forth by a specific reference in such filing.

Item

9.01.

Financial

Statement and Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

3.1

Certificate

of Amendment to certificate of incorporation

99.1

Press

Release dated August 21, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

KAIROS

PHARMA, LTD.

Dated:

August 21, 2026

By:

/s/

John S. Yu

Name:

John

S. Yu

Title:

Chief

Executive Officer and Chairman of the Board of Directors

EX-3.1

Filename: ex3-1.htm · Sequence: 2

Exhibit

3.1

CERTIFICATE

OF AMENDMENT TO

THE

CERTIFICATE OF INCORPORATION

KAIROS

PHARMA, LTD.

Kairos

Pharma, Ltd., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby

certify as follows:

The

Corporation was originally incorporated, and the original Certificate of Incorporation was filed with the Secretary of State of the

State of Delaware on May 10, 2023, under the name “Kairos Pharma, Ltd.”

This

Certificate of Amendment to the Certificate of Incorporation (the “Certificate of Amendment”) was duly adopted by the

Board of Directors of the Corporation in accordance with Sections 141 and 242 of the General Corporation Law of the State of Delaware.

Article

IV, Section 4.1 of the Certificate is hereby amended and restated to read in its entirety as follows:

“ARTICLE

Section

4.1. The total number of shares of all classes of stock that the Corporation has authority to issue is 120,000,000 shares, consisting

of two classes: 100,000,000 shares of Common Stock, $0.001 par value per share (“Common Stock”), and 20,000,000

shares of Preferred Stock, $0.001 par value per share (“Preferred Stock”).

Effective

as of 12:01 AM Eastern time on September 1, 2026 (the “Effective Time”) each seven (7) shares of the Corporation’s

Common Stock, par value $0.001 per share, issued and outstanding shall be combined into one share of Common Stock, par value $0.001 per

share, of the Corporation (the “Reverse Stock Split”). No fractional shares shall be issued.

Any fractional shares that would otherwise be issuable as a result of the Reverse Stock Split will be rounded up to the nearest whole

share; provided, that where shares are held in certificated form, the surrender of a stockholder’s Old Certificates (as defined

below) will be required. Each certificate that immediately prior to the Effective Time represented shares of Common Stock (“Old

Certificates”) shall thereafter represent that number of shares of Common Stock into which the shares of Common Stock represented

by the Old Certificate shall have been combined, subject to the treatment of fractional share interests as described above.”

This

Certificate of Amendment shall be effective as of the Effective Time.

This

Certificate of Amendment was submitted to the stockholders of the Corporation and was duly adopted and approved in accordance with

the provisions of Section 242 of General Corporate Law of the State of Delaware at the annual meeting of the stockholders of the

Corporation.

WITNESS WHEREOF, Kairos Pharma, Ltd. has caused this Certificate of Amendment to be signed by a duly authorized officer of the Corporation

on August 21, 2026.

Kairos

Pharma, Ltd.

By:

/s/

John S. Yu

Name:

John

S. Yu

Title:

Chief

Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 3

Exhibit

99.1

Kairos

Pharma Announces 1-for-7 Reverse Stock Split

LOS

ANGELES – August 21, 2026 – Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused

on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common

stock at a ratio of 1-for-7 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on September

1, 2026 at 12:01 a.m. ET (the “Effective Time”), with shares expected to begin trading on the NYSE American on a split-adjusted

basis at market open on September 1, 2026 under the existing trading symbol “KAPA” and a new CUSIP number of 48301N203.

connection with the Reverse Stock Split, every seven (7) shares of the Company’s common stock issued and outstanding immediately

prior to the Effective Time will be automatically reclassified and combined into one (1) share of common stock. No fractional

shares of common stock will be issued as a result of the Reverse Stock Split. Instead, the Company will issue to holders of record who

were entitled to a fraction of a share as a result of the Reverse Stock Split, a fraction of a share of common stock as is necessary

to round up to the nearest whole share. For shares held through The Depository Trust Company (“DTC”), fractions of shares

will be issued as is necessary to round up to the nearest whole share at the DTC participant level. Brokers, banks or other nominees

holding shares in “street name” will be instructed to effect the Reverse Stock Split for their beneficial holders; however,

such brokers, banks or other nominees may apply their own specific procedures for processing the Reverse Stock Split.

Upon

the effectiveness of the Reverse Stock Split, the conversion rates of the Company’s outstanding convertible notes, the number of

shares of common stock issuable upon exercise of outstanding warrants and the exercise prices thereof, and the number of shares subject

to outstanding equity awards under the Company’s equity incentive plans (and the applicable exercise prices thereof), will each

proportionately be adjusted pursuant to their respective terms and as determined by the Company’s board of directors to reflect

the 1-for-7 Reverse Stock Split ratio.

The

Reverse Stock Split will have no effect on the par value of the Company’s common stock, and each stockholder’s percentage

ownership interest in the Company and proportional voting power remains unchanged, except for minor changes resulting from the treatment

of fractional shares. Following the Reverse Stock Split, the par value of the common stock will remain unchanged at $0.001 par value

per share. The Reverse Stock Split will not change the number of authorized shares of common stock or preferred stock.

The

Reverse Stock Split is intended to reduce the number of outstanding shares and proportionately increase the per-share trading price and

help the Company maintain compliance with the requirements for continued listing on the NYSE American.

VStock

Transfer, LLC is acting as the transfer and exchange agent for the Reverse Stock Split. Stockholders who hold registered shares in book-entry

form at VStock Transfer, LLC are not required to take any action to receive split-adjusted shares. Stockholders who hold shares

through a broker, bank or other nominee will have their positions automatically adjusted and are not required to take any action.

About

Kairos Pharma Ltd.

Based

in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural

biology to overcome drug resistance and immune suppression in cancer. Kairos Pharma’s lead candidate, ENV-105, is an antibody that

targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims

to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. For more

information, visit kairospharma.com.

Kairos

Pharma Forward Looking Statements

This

press release may contain forward-looking statements, including information about management’s view of Kairos Pharma’s future

expectations, plans and prospects, within the meaning of the federal securities laws, including the safe harbor provisions under The

Private Securities Litigation Reform Act of 1995 (the “Act”). In particular, when used in the preceding discussion, the words

“may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,”

“believe,” “estimate,” “predict,” “potential,” “continue,” “likely,”

“will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar

expressions are intended to identify forward-looking statements within the meaning of the Act and such laws, and are subject to the safe

harbor created by the Act and applicable laws. Any statements made in this news release other than those of historical fact, about an

action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other

factors, which may cause the results of Kairos Pharma to be materially different than those expressed or implied in such statements.

The forward-looking statements include statements regarding the anticipated effects of the proposed Reverse Stock Split, the Company’s

capital structure, per-share trading price, capital markets profile, per-share metrics, and ability to attract institutional investors,

and others that are included from time to time in filings made by Kairos Pharma with the Securities and Exchange Commission, including,

but not limited to, in the “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” sections

of its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. These reports and filings are available at www.sec.gov. The Company

cautions that the foregoing list of important factors is not complete. All subsequent written and oral forward-looking statements attributable

to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced

above. Other unknown or unpredictable factors also could have material adverse effects on Kairos Pharma’s future results and/or

could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The

forward-looking statements included in this press release are made only as of the date hereof. The Company undertakes no obligation to

update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required

by law.

Contact:

investors@kairospharma.com

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 4

Binary file (4120 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 20

v3.26.1

Cover

Aug. 21, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 21, 2026

Current Fiscal Year End Date

--12-31

Entity File Number

001-42275

Entity Registrant Name

Kairos

Pharma, Ltd.

Entity Central Index Key

0001962011

Entity Tax Identification Number

46-2993314

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2355

Westwood Blvd

Entity Address, Address Line Two

#139

Entity Address, City or Town

Los

Angeles

Entity Address, State or Province

Entity Address, Postal Zip Code

90064

City Area Code

(310)

Local Phone Number

948-2356

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock $0.001 per share

Trading Symbol

KAPA

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name:

dei_CurrentFiscalYearEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:gMonthDayItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration